Skip to main content
Premium Trial:

Request an Annual Quote

WashU Researcher Reports on Findings from 50 Breast Cancer Genomes at AACR

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mutation patterns in 50 breast cancer genomes are offering new insights into the genetic complexity of the disease, Washington University oncologist Matthew Ellis reported at the American Association for Cancer research annual meeting in Orlando this weekend.

"Cancer genomes are extraordinarily complicated," Ellis said in a statement, adding the result of his and his colleagues research "explains our difficulty in predicting outcomes and finding new treatments."

Last year, researchers from Washington University's Genome Institute and elsewhere published a study in Nature describing findings for a triple negative breast cancer genome and matched normal genome from an African American woman.

For the current study, Ellis and co-workers sequenced matched tumor-normal samples from 50 women with estrogen receptor positive breast cancers to about 30 times coverage each.

The samples were obtained through an American College of Surgeons Oncology Group clinical trial, in conjunction with collaborators from Washington University School of Medicine and Barnes-Jewish Hospital's Alvin J. Siteman Cancer Center.

Despite detecting a preponderance of mutations — more than 1,700 overall — the researchers found just a handful of genes were altered in multiple tumor samples.

Among them: PIK3CA and TP53, genes that have been implicated in past studies of breast cancer. In the 50 tumors tested, researchers saw PIK3CA mutations in around 40 percent of tumors and TP53 mutations in roughly one-fifth of tumors.

Three additional genes — MAP3K1, ATR and MYST — were each mutated in about 10 percent of the breast cancers, while another 21 genes were significantly linked to breast cancer but mutated in tumors from just two or three of the women.

Because 24 of the 50 tumors tested came from women whose cancers were known to be resistant to an estrogen-lowering treatment given prior to surgery, the team hopes that the whole-genome data will also provide clues to the sorts of treatment resistance mechanisms that exist in ER-positive breast cancers.

Moreover, those involved in the study are keen to use information from the newly sequenced genomes as a jumping off point for new breast cancer treatment strategies — particularly for genes that are already being considered as possible drug targets in other types of cancer.

"We get good therapeutic ideas from the genomic information," Ellis said. "The near-term goal is to use information on whole genome sequencing to guide a personalized approach to the patient's trea

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.